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ABSTRACT
Chromobox (CBX) family proteins are canonical components in polycomb 
repressive complexes 1 (PRC1), with epigenetic regulatory function and 
transcriptionally repressing target genes via chromatin modification. A plethora of 
studies have highlighted the function specifications among CBX family members in 
various cancer, including lung cancer, colon cancer and breast cancer. Nevertheless, 
the functions and prognostic roles of distinct CBX family members in breast cancer 
(BC) remain elusive. In this study, we reported the prognostic values of CBX family 
members in patients with BC through analysis of a series of databases, including 
CCLE, ONCOMINE,  Xena Public Data Hubs, and Kaplan-Meier plotter. It was found 
that the mRNA expression of CBX family members were noticeably higher in BC than 
normal counterparts. CBX2 was highly expressed in Basal-like and HER-2 subtypes, 
while CBX4 and CBX7 expressions were enriched in Luminal A and Luminal B subtypes 
of BC. Survival analysis revealed that CBX1, CBX2 and CBX3 mRNA high expression 
was correlated to worsen relapse-free survival (RFS) for all BC patients, while CBX4, 
CBX5, CBX6 and CBX7 high expression was correlated to better RFS in this setting. 
Noteworthily, CBX1 and CBX2 were associated with chemoresistance whereas CBX7 
was associated with tamoxifen sensitivity, as well as chemosensitivity in breast 
tumors. Therefore, we propose that CBX1, CBX2 and CBX7 are potential targets for 
BC treatment. The results might be beneficial for better understanding the complexity 
and heterogeneity in the molecular underpinning of BC, and to develop tools to more 
accurately predict the prognosis of patients with BC.
INTRODUCTION
In addition to gene mutation or dysregulated 
amplification, abnormality in epigenetic regulation 
has been recognized to play a prominent role in the 
tumorigenesis and development of a broad range of 
cancer types, including lung, colorectal and breast cancer 
[1-6]. Chromobox (CBX) family proteins are canonical 
components in polycomb repressive complexes 1 (PRC1), 
which are epigenetic regulatory complexes that conduct 
transcriptional repression of target genes via modifying 
the chromatin [7].
Up to now, eight CBX proteins in human genome 
have been identified, with similar chemical structure 
that contains a single N-terminal chromodomain [8]. 
The CBX proteins are all involved in the regulation of 
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heterochromatin, gene expression, and developmental 
programs. CBX proteins are further divided into two 
groups: (1) CBX1, CBX3, and CBX5, also known as 
heterochromatin protein 1β (HP1β), HP1γ, and HP1α, 
respectively; (2) CBX2, CBX4, CBX6, CBX7, and 
CBX8, all having a C-terminal polycomb repressor box, 
serve as canonical components in PRC1 [8]. However, 
studies showed that different polycomb group CBX 
family proteins were associate with distinct regions of 
chromatin using nonhomologous protein sequences, which 
imply a specific target of individual polycomb group 
protein [9, 10].
Increasing evidences have indicated that 
CBX proteins play pivotal roles in tumor initiation, 
progression, and development by blocking differentiation 
and promoting self-renewal of cancer stem cells [11]. 
Deregulation of CBX proteins in various cancers has been 
reported [12-17]. Morey and colleagues have suggested 
that there was non-overlapping function of the polycomb 
group CBX family of proteins in embryonic stem cells 
[18]. Recently, Rong-gang MA and colleagues have 
reviewed the emerging role of CBX proteins in a number 
of physiological and pathological conditions, suggesting 
deregulation of CBX proteins were associated with 
many cancer types [7]. Study by Jie Li and colleagues 
indicated that CBX4 was a critical regulator of tumor 
angiogenesis by governing HIF-1a protein [19]. Kanako 
Shinjo’s findings demonstrated that expression CBX7 
was associated with poor prognosis in ovarian clear 
cell adenocarcinoma via TRAIL-induced apoptotic 
pathway regulation [20]. However, the roles of distinct 
CBX members in contribution to tumorigenesis and 
development of BC are largely unknown.
In the current study, we extended the research field 
to BC based on a variety of large databases, with purpose 
of determining the prognostic values of distinct CBX 
family members in BC.
RESULTS
CBX family members were distinctively 
overexpressed in breast cancer
Hitherto, 8 CBX family members have been 
identified in human cancers. CCLE analysis demonstrated 
that mRNA expression level of CBX2 in breast cancer 
listed the fifth highest among all cancer types (Figure 
1A). Also, other CBX family members like CBX3, CBX4, 
CBX5, CBX6, CBX7 and CBX8 express different patterns 
in breast cancer compared with other cancer types cells 
(Supplementary Figure 1, 2).
ONCOMINE analysis revealed that CBX2, CBX3, 
CBX4, CBX7 and CBX8 mRNA expression was 
significantly higher in BC than normal samples (Figure 
1B). CBX2 transcripts were 9.378-fold elevated in 
breast cancer samples as compared with normal tissues 
in a dataset with 593 samples that derived from TCGA 
database (Supplementary Figure 3A).
CBX3 was 2.498-fold elevated in breast cancer 
samples as compared with normal tissues (p=8.88E-9) 
(Supplementary Figure 3B). CBX4 was 2.604-fold 
elevated in breast cancer samples as compared with 
normal tissues (p=1.19E-24) (Supplementary Figure 
3C). CBX7 was 8.782-fold elevated in breast cancer 
samples as compared with normal tissues (p=1.83E-13) 
(Supplementary Figure 3D). CBX8 was 2.048-fold 
elevated in breast cancer samples as compared with 
normal tissues (p=1.10E-16) (Supplementary Figure 3E).
CBX2 was associated with Basal-like and HER-2 
subtypes, while CBX4 and CBX7 was correlated 
to Luminal A and Luminal B subtypes of breast 
cancer
In Xena Public Data Hubs analysis (Figure 2), the 
expression of CBX2 in Basal-like and HER-2 subtypes 
was significantly higher than Luminal A and Luminal 
B subtypes of BC. However, higher mRNA expressions 
of CBX4 and CBX7 were detected in Luminal A and 
Luminal B subtypes than Basal-like and HER-2 subtypes 
of breast cancer. CBX1, CBX3, CBX5, CBX6 and CBX8 
mRNA expression have no significant difference across 
various subtypes of BC.
Elevated CBX1 expression predicted poor 
survival in breast cancer patients, especially in 
the ER positive and the subgroup treated with 
adjuvant chemotherapy only
We next assessed the prognostic effect of individual 
CBX member in patients with BC. CBX1 mRNA high 
expression was associated with shorter RFS in all 
BC patients (HR=1.26, p=3.1e-05) (Figure 3A). Sub-
analysis indicated that CBX1 mRNA high expression was 
correlated to shorter RFS in BC patients with ER positive 
tumors (HR=1.29, p=1e-04) (Figure 3B), but not in ER 
negative tumors (HR=1.09, p=0.4) (Figure 3C).
Moreover, CBX1 mRNA high expression was 
correlated to shorter RFS in BC patients with Luminal 
A tumors (HR=1.24, p=0.014) and Luminal B tumors 
(HR=1.31, p=0.0053) (Figure 3D, 3E). However, there 
was no significant difference in RFS in patients either 
with Basal-like (HR=1.18, p=0.19) or HER-2 positive 
(HR=1.1,  p=0.63) tumors between high and low CBX1 
mRNA expression (Figure 3F, 3G).
Of noteworthy, the results demonstrated that CBX1 
high expression was significantly correlated to shorter RFS 
in patients who have received adjuvant chemotherapy only 
(HR=1.36, p=0.045), indicating a potential role of CBX1 
in contribution to chemoresistance in BC (Figure 3H). RFS 
sub-analysis of CBX1 chemotherapy include or exclude 
were provided in Supplementary Figure 8A and 8B.
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Figure 1: The mRNA expression of CBX family members in different cancer types. (A) The mRNA expression level of 
CBX2 analyzed from CCLE database. CBX2 ranked the fifth highest in a variety of cancer cell line (shown in red frame). (B) CBX 
family expressions (cancer vs. normal tissue) analyzed with ONCOMINE database. The graphic demonstrated the numbers of datasets 
with statistically significant mRNA over-expression (red) or down-expression (blue) of the target gene. The P value threshold is 0.01. 
The number in each cell represents the number of analyses that meet the threshold within those analysis and cancer types. The gene rank 
was analyzed by percentile of target gene in the top of all genes measured in each research. Cell color is determined by the best gene rank 
percentile for the analyses within the cell.
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Figure 2: CBX members were distinctively high expressed in breast cancer subtype from Xena analysis. (A) The mRNA 
expression level of CBX1 in a variety of BC subtype. (B) The mRNA expression level of CBX2 in a variety of BC subtype. (C) The mRNA 
expression level of CBX3 in a variety of BC subtype. (D) The mRNA expression level of CBX4 in a variety of BC subtype. (E) The mRNA 
expression level of CBX5 in a variety of BC subtype. (F) The mRNA expression level of CBX6 in a variety of BC subtype. (G) The mRNA 
expression level of CBX7 in a variety of BC subtype. (H) The mRNA expression level of CBX8 in a variety of BC subtype.
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Elevated CBX2 expression predicted poor 
survival in breast cancer patients, especially in 
the ER-positive, HER-2 negative, lymph node-
positive and the subgroup treated with adjuvant 
chemotherapy only
CBX2 mRNA high expression was significantly 
correlated with shorter RFS in all BC patients (HR=1.79, 
p=2.2e-13) (Figure 4A). CBX2 mRNA high expression 
was correlated to shorter RFS in BC patients with ER 
positive tumors (HR=1.69, p=1.3e-07) (Figure 4B), but 
not in ER negative tumors (HR=1.07, p=0.62) (Figure 
4C). CBX2 mRNA high expression was correlated to 
shorter RFS in BC patients with HER-2 negative tumors 
(HR=2.19, p=4.3e-07) (Figure 4E), but not in HER-2 
positive tumors (HR=1.22, p=0.47) (Figure 4D).
Figure 3: The prognostic values of CBX1 in breast cancer. (A) Elevated CBX1 mRNA level was significantly associated with 
shorter RFS in all BC patients. High mRNA level of CBX1 was significantly associated with poorer RFS both in ER positive (B), but not 
ER negative (C) BC patients. (D-G) High mRNA expression of CBX1 was significantly associated with shorter RFS in Luminal A and 
Luminal Bsubtype BC patients, but not in Basal-like and HER-2 subtype BC patients. (H) High mRNA level of CBX1 was associated with 
worse RFS in BC patients who have received adjuvant chemotherapy only.
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CBX2 mRNA high expression was correlated to 
shorter RFS in BC patients with lymph node-positive 
tumors (HR=2.11, p=7.7e-09) (Figure 4F), but not in 
node-negative tumors (HR=1.42, p=0.7) (Figure 4G). 
CBX2 mRNA high expression was correlated to shorter 
RFS in BC patients with Luminal A (HR=1.74, p=1.3e-05) 
(Figure 4H) and Luminal B tumors (HR=1.37, p=0.042) 
(Figure 4I), but not in Basal-like tumors (HR=1.19, p=0.3) 
(Figure 4J) and HER-2 subtype tumors (HR=1.03, p=0.92) 
(Figure 4K).
Notably, the results demonstrated that CBX2 high 
mRNA expression was significantly correlated to shorter 
RFS in patients who have received adjuvant chemotherapy 
only (HR=2.78, p=3.5e-05) (Figure 4L), indicating a 
potential role of CBX2 in contribution to chemoresistance 
in BC. (RFS sub-analysis of CBX2 chemotherapy include 
or exclude were provided in the Supplementary Figure 8C-
8D).
Elevated CBX6 expression predicted better 
survival in breast cancer patients, especially in 
the subgroup of ER-positive and HER-2 negative 
tumors
In Figure 5, CBX6 high mRNA expression was 
significantly associated with longer RFS in all BC patients 
(HR=0.73, p=2.7e-08) (Figure 5A). In particular, sub-
analysis revealed that high mRNA expression of CBX6 
was significantly associated with better survival in ER 
positive (HR=0.73, p=9e-07) (Figure 5B), HER-2 negative 
tumors (HR=0.73, p=2.7e-08) (Figure 5E), and Luminal A 
subtype patients (HR=0.69, p=1.7e-5) (Figure 5F), but not 
in HER-2 positive (HR=0.97, p=0.9) (Figure 5D), Luminal 
B subtype patients (HR=0.86, p=0.14) (Figure 5G), Basal-
like subtypes BC patients (HR=1.02, p=0.89) or HER-2 
subtype (HR=0.97, p=0.9) (Figure 5H, 5I).
Elevated CBX7 expression predicted better 
survival in breast cancer patients, especially in 
the subgroup treated with tamoxifen only and 
adjuvant chemotherapy only
In Figure 6, CBX7 high mRNA expression was 
significantly associated with better prognosis in all BC 
patients (HR=0.53, p<1e-16) (Figure 6A). In particular, 
sub-analysis revealed that high mRNA expression of 
CBX7 was significantly associated with better survival in 
both ER positive (HR=0.55, p<1e-16) and ER negative 
(HR=0.68, p=0.00028) patients (Figure 6B, 6C), as well 
as those with Luminal A (HR=0.55, p=1.1e-11) and 
Luminal B (HR=0.68, p=7.9e-05) tumors (Figure 6D, 
6E). Similar trend was also found in patients with Basal-
like (HR=0.69, p=0.0035) (Figure 6F) and HER-2 subtype 
tumor (HR=0.64, p=0.022) (Figure 6G).
Of noteworthy, the results demonstrated that CBX7 
high mRNA expression was significantly correlated to 
longer RFS in patients who treated with tamoxifen only 
(HR=0.74, p=0.037) (Figure 6I), indicating a potential role 
of CBX7 in contribution to tamoxifen sensitivity in breast 
cancer. RFS sub-analysis of CBX7 endocrine-therapy 
include or exclude were provided in Supplementary Figure 
8E and 8F. The results also demonstrated that CBX7 high 
mRNA expression was significantly correlated to longer 
RFS in patients who have received adjuvant chemotherapy 
only (HR=0.7, p=0.023) (Figure 6H), indicating a potential 
role of CBX7 in contribution to chemosensitivity in breast 
cancer.
DISCUSSION
Breast cancer (BC) is virtually a heterogeneous 
disease that comprising a variety of subtypes associated 
with distinct biological and clinical features [21, 22]. 
Latest technologies have unraveled the molecular 
underpinning of several characteristics of breast cancer, 
including histological grade and metastatic propensity, and 
have led to the identification of prognostic and predictive 
gene expression signatures [23, 24].
Apart from abnormality in transcriptome, disorder 
in epigenetic regulation also plays significant role in the 
tumorigenesis and development of BC [1, 25]. Chromobox 
(CBX) family proteins are canonical components in 
PRC1(polycombrepressive complexes 1), which is one of 
the best characterized polycomb group (PcG) complexes, 
with epigenetic regulatory function of conducting 
transcriptional repression of target genes via modifying 
the chromatin [7, 26].
Previously, several groups have shown that aberrant 
CBX member expression were observed in certain cancers 
tissues [27-29]. CBX1 levels were prominent in prostate 
cancer [30]. CBX4 was elevated in Hepatocellular 
carcinoma [31] whereas CBX6 was decreased in 
glioblastoma [32]. CBX7 was upregulated in prostate 
cancer [33] and gastric cancer [34] while declined in 
thyroid cancer [35], lung cancer and colon cancer [36, 
37]. However, litter is understood in the expression of 
individual CBX member in breast cancer.
Results from our analysis suggested that almost all 
CBX family members were distinctively high-expressed in 
BC comparing to normal controls, implying their unique 
roles in BC. Even though no data of CBX1 in the dataset, a 
study by Young-Ho Lee and colleagues reported that CBX 
was heterogeneously distributed in BC samples and high 
expression of CBX1 had a positive correlation to Ki-67 
and associated with poorly differentiated breast tumors 
and with a significantly poor prognosis [38].
Our finding demonstrated that, through using Xena 
database analysis, the expression of CBX2 in Basal-
like and HER-2 subtypes was significantly higher than 
Luminal subtypes breast cancer. This was consistent with 
the report by Chen and colleagues that protein expression 
of CBX2 was significantly higher in tumor tissues than 
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adjacent normal tissues, and similarly, CBX2 was found 
to be significantly associated with positive HER-2 status 
[39]. Moreover, higher mRNA expressions of CBX4 and 
CBX7 were detected in Luminal subtypes than Basal-like 
subtypes of breast cancer. The disparate enrichment of 
CBX proteins in various subtypes of breast cancer may be 
one of the underlying mechanisms pertinent to different 
biological properties, as well as diverse prognosis.
Figure 4: The prognostic values of CBX2 in breast cancer. (A) Elevated CBX2 mRNA level was significantly associated with 
poorer RFS in all BC patients. (B-C) High mRNA level of CBX2 was significantly associated with shorter RFS in ER positive, but not ER 
negative BC patients. (D-E) High mRNA level of CBX2 was significantly associated with shorter RFS in HER-2 negative, but not HER-2 
positive BC patients. (F-G) High mRNA level of CBX2 was significantly associated with shorter RFS both in LN (lymph node) positive, 
but not LN negative BC patients. (H-K) High mRNA expression of CBX2 was significantly associated with shorter RFS in Luminal A and 
Luminal B subtype BC patients, but not in Basal-like or HER-2 subtype BC patients. (L) High mRNA level of CBX2 was associated with 
worse RFS in BC patients who have received adjuvant chemotherapy only.
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In the current study, it was found that CBX1, 
CBX2 and CBX3 mRNA high expression was correlated 
to worsen RFS for all BC patients (Figure 3, 4; 
Supplementary Figure 4). CBX4, CBX5, CBX6 and 
CBX7 mRNA high expression was correlated to better 
RFS for all BC patients (Figure 5, 6; Supplementary 
Figure 5, 6). No significantly difference was found 
between the group of CBX8 high expression and low 
expression in RFS for all BC patients (Supplementary 
Figure 7). RFS sub-analysis of CBX3, CBX4, CBX5, 
Figure 5: The prognostic values of CBX6 in breast cancer. (A) High mRNA level of CBX6 was significantly associated with 
longer RFS in all BC patients. (B-C) High mRNA level of CBX6 was significantly associated with longer RFS in ER positive, but not ER 
negative BC patients. (D-E) High mRNA level of CBX6 was significantly associated with longer RFS in HER-2 negative BC patients, but 
not in HER-2 positive BC patients. (F-I) High mRNA level of CBX6 was significantly associated with longer RFS in Luminal A subtype 
BC patients, but not in Luminal B, Basal-like or HER-2 subtype BC patients.
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CBX8 were also provided in Supplementary Figure 
4-7. Our study further demonstrated that high CBX1 
expression predicts poor survival in BC patients, 
especially in those with ER-positive tumors. These 
results partly agree with report by Young-Ho Lee and 
colleagues that high CBX1 expression group displayed 
more aggressive types of breast cancers, including 
Basal-like and Luminal B subtypes, and associated with 
shorter disease-free survival (DFS) and overall survival 
(OS) [38]. However, more evidences remain needed to 
validate different expression profiles of CBX1 in various 
molecular subtypes of BC.
Figure 6: The prognostic values of CBX7 in breast cancer. (A) High mRNA level of CBX7 was significantly associated with 
longer RFS in all BC patients. (B-C) High mRNA level of CBX7 was significantly associated with longer RFS in both ER positive and ER 
negative BC patients. (D-G) High mRNA level of CBX7 was significantly associated with better RFS in Luminal A, Luminal B, Basal-like 
and HER-2 subtype BC patients. (H, I) High mRNA level of CBX7 was associated with longer RFS in BC patients who have received 
adjuvant chemotherapy only or tamoxifen only subgroup.
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It was suggested in the study that high mRNA 
expression of CBX2 predicts poor survival in BC patients. 
In line with several studies reporting that CBX2 was 
a potential drug target in human cancers. In a human 
study, the depletion of CBX2 resulted in decreased 
cell proliferation and increasing levels of apoptosis, 
emphasizing the requirement of CBX2 in the maintenance 
of hematopoietic stem cell [40]. CBX2 was found to 
be phosphorylated in cell lines that proliferate rapidly 
in culture, whereas it was not phosphorylated in most 
tissues examined [41]. CBX2 protein expression levels 
were inversely associated with prognosis in breast cancer 
patients. CBX2 expression was associated with clinical 
features, including positive lymph node metastasis status, 
large tumor size and HER-2 positive status [14]. CBX2 
upregulation and amplification significantly correlated 
with metastatic progression and lower overall survival in 
many cancer types, particularly those of the breast [39].
Moreover, in subgroup analysis, we found that 
elevated CBX1 and CBX2 expression were correlated 
to worse prognosis in the patients treated with adjuvant 
chemotherapy only, which indicated that CBX1 and CBX2 
might play pivotal roles in chemoresistance. Young-Ho 
and colleagues found that HP1β (CBX1) depleted BC 
cells were hypersensitive to PARP inhibitor, compromised 
HP1βabundance may serve as a useful predictive marker 
for chemotherapy [38]. Chen and colleagues revealed 
that OS time of BC patients treated with Taxol was 
significantly lower than that of patients who did not 
receive Taxol treatment in the high CBX2 expression 
group. However, no significant difference in OS time was 
identified between patients treated with or without Taxol 
in the low CBX2 expression group [14]. Therefore, CBX2 
might be a novel biomarker for the selection of appropriate 
chemotherapy regimens for BC patients.
Although study showed that induced CBX6 
overexpression inhibited glioblastoma cell proliferation 
[32], which implying CBX6 to be a tumor suppressor 
in certain cancer. However, few researches covered the 
prognostic value of CBX6 in BC. In our study, we first 
reported that elevated CBX6 expression predicted better 
survival in BC patients, specifically in the subgroup with 
ER positive and HER-2 negative tumors. Therefore, 
it is extrapolated that CBX6 might be an independent 
prognostic factor in BC.
Most interestingly, our study suggested that elevated 
CBX7 expression predicted better survival in BC patients, 
and was correlated with poor prognosis in patients 
treated with tamoxifen only and adjuvant chemotherapy 
only. CBX7 is the most characterized CBX protein in 
cancer-associated studies which plays a critical role 
in cancer progression [12]. Also, Ni, S et al. reported 
that CBX7 inhibited cell proliferation, migration, and 
invasion through the inhibition of PTEN/AKT signaling 
in pancreatic cancer [42]. Studies showed that loss of 
the CBX7 expression correlated with a highly malignant 
phenotype in thyroid cancer [35], or a more aggressive 
biological behavior in pancreatic cancer [13]. Multivariate 
analysis showed that combined EZH2/CBX7 status was an 
independent prognostic factor [43].
Specially, it has been reported that CBX7 
inhibited breast tumorigenicity through DKK-1-
mediated suppression of the Wnt signaling pathway, 
suggesting that CBX7 was a critical tumor suppressor 
in human BC [44]. In subgroup analysis, we found that 
high expression of CBX7 was significantly correlated 
to longer RFS in patients who have received adjuvant 
chemotherapy only, indicating a potential role of 
CBX7 in contribution to chemosensitivity in BC. Also, 
Cacciola and colleagues revealed that restoration of 
CBX7 expression increased the susceptibility of human 
lung carcinoma cells to irinotecan treatment [45]. 
Therefore, enhancement of CBX7 expression might be 
a potential measure for improving treatment response 
to chemotherapy.
In summary, CBX1, CBX2 and CBX3 mRNA 
high expression was associated with worsen RFS for all 
BC patients. CBX4, CBX5, CBX6 and CBX7 mRNA 
high expression was correlated to better RFS for all BC 
patients. CBX1 and CBX2 might be important predictor 
of chemoresistance in breast tumors. High level of CBX7 
in breast tumors might portend a better response when 
treated with tamoxifen or chemotherapeutical agents. 
CBX1, CBX2 and CBX7 could be potential targets of 
individualized therapy for BC patients. These results will 
help to better understand the complexity and heterogeneity 
in the molecular biology of BC, as well as to develop 
strategy to more accurately tailor treatment and predict 
survival outcome for patients with BC.
MATERIALS AND METHODS
CCLE analysis
The mRNA levels of CBX members in a series 
of cancers were analyzed by CCLE database (https://
portals.broadinstitute.org/ccle/home), which is an online 
encyclopedia of a compilation of gene expression, 
chromosomal copy number and massively parallel 
sequencing data from 947 human cancer cell lines, 
to facilitate the identification of genetic, lineage, and 
predictors of drug sensitivity, as described in our previous 
study [46].
ONCOMINE analysis
The mRNA levels of distinct CBX family members 
in diverse cancer types were determined through analysis 
in ONCOMINE database (www.oncomine.org), which is a 
publicly accessible online database with cancer microarray 
information to facilitate discovery from genome-wide 
expression analyses.
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In this study, a p-value was calculated through 
students’t-test for comparison between datasets derived 
from cancer specimens and normal controls. The fold 
change was defined as 2 and p value was set up at 0.01. 
Significant correlations can be found in a series of BC 
researches, as displayed in typical figures.
Xena public data hubs
UCSC Xena browser (http://xena.ucsc.edu/) was 
used to obtain The Cancer Genome Atlas (TCGA) breast 
cancer data and to evaluate CBX family members’ mRNA 
expression in different subtypes of human breast cancer.
The Kaplan-Meier plotter survival analysis
Prognostic values of featured CBX members that 
found specifically high expressed in BC samples were 
subsequently evaluated by showing the relapse-free 
survival (RFS), which was based on the analysis in the 
Kaplan-Meier plotter (www.kmplot.com). The log-rank P 
was calculated accordingly, as shown on the webpage. [47]
Additional message
RFS analysis of CBX3, CBX4, CBX5, CBX8 in 
the Kaplan-Meier plotter were showed in Supplementary 
Figure 4, 5, 6, 7, and 8.
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